Cancel
Ali Ozes
Founder, CEO & Board Member
@
Altay Therapeutics
See Linkedin
About Ali Ozes
Ali Ozes is the founder, CEO, and board member of a biotech company, known for developing a scalable method to identify novel small molecule binding domains and creating three first-in-class inhibitors targeting previously undruggable transcription factors.
Known information
Ali Ozes holds the positions of founder, CEO, and board member at his biotech company, where he has pioneered the development of a scalable method that identifies novel small molecule binding domains with direct nanomolar (nM) binding to target transcription factors (TFs). His innovative platform facilitates the discovery of small molecule binding sites within intrinsically disordered domains, aiming to develop more specific and safer therapies by targeting disease-causing TFs. Ozes has successfully developed three first-in-class inhibitors aimed at treating fibrosis (IPF & NASH), Ewing’s Sarcoma/Prostate Cancer, and Facioscapulohumeral muscular dystrophy (FSHD), focusing on transcription factors previously considered undruggable.
About Altay Therapeutics
Altay Therapeutics, based in California, specializes in developing small molecule drugs for chronic liver diseases, including liver fibrosis and liver cancer, aiming to impact a market of over 20 million Americans.
Report inaccurate information
